Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

520
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
520
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Angina IV: Management01:26

Angina IV: Management

368
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
368
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

6.2K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.2K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

711
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
711
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

2.4K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dehydrocostus lactone attenuates hyperthyroidism-induced myocardial remodeling and injury via modulation of the oxidative stress-autophagy-inflammation axis with involvement of mTOR signaling.

Tissue & cell·2026
Same author

Advanced cardiac organoid model for studying doxorubicin-induced cardiotoxicity.

Toxicological sciences : an official journal of the Society of Toxicology·2025
Same author

Advanced Cardiac Organoid Model for Studying Doxorubicin-Induced Cardiotoxicity.

bioRxiv : the preprint server for biology·2025
Same author

Mechanisms of nebivolol-mediated effects on bFGF-induced vascular smooth muscle cell proliferation and migration.

Current research in pharmacology and drug discovery·2025
Same author

Exercise training remodels inguinal white adipose tissue through adaptations in innervation, vascularization, and the extracellular matrix.

Cell reports·2023
Same author

Calcium signaling induced by 15-deoxy-prostamide-J2 promotes cell death by activating PERK, IP3R, and the mitochondrial permeability transition pore.

Oncotarget·2022

Related Experiment Video

Updated: Mar 2, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Dyslipidemia management update.

Yingzi Chang1, Jacques Robidoux2

  • 1A.T. Still University, Kirksville College of Osteopathic Medicine, Department of Pharmacology, Kirksville, MO 63501, USA.

Current Opinion in Pharmacology
|May 21, 2017
PubMed
Summary

New cholesterol drugs, like PCSK9 antibodies, significantly lower LDL-C in patients with hypercholesterolemia. Novel approaches targeting reverse cholesterol transport may offer future cardiovascular risk reduction strategies.

More Related Videos

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

515
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.8K

Related Experiment Videos

Last Updated: Mar 2, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

515
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.8K

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Hypercholesterolemia is a known risk factor for atherosclerotic cardiovascular disease (ASCVD).
  • Therapeutic strategies traditionally focus on reducing low-density lipoprotein-cholesterol (LDL-C) and increasing high-density lipoprotein-cholesterol (HDL-C).
  • Conventional cholesterol-lowering medications include statins, ezetimibe, and bile-acid sequestrants.

Purpose of the Study:

  • To review recent advancements in cholesterol-lowering therapies.
  • To evaluate the efficacy of novel drug classes for hypercholesterolemia.
  • To explore potential new therapeutic targets for cardiovascular risk reduction.

Main Methods:

  • Review of clinical trials and recent approvals of novel cholesterol-lowering agents.
  • Analysis of the impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies on LDL-C levels.
  • Evaluation of apolipoprotein B-100 (Apo B-100) antisense and microsomal triglyceride transfer protein (MTP) inhibitors.
  • Assessment of outcomes from trials investigating HDL-raising drugs and reverse cholesterol transport.

Main Results:

  • PCSK9 antibodies, when added to statin therapy, can reduce LDL-C by up to 60%.
  • ApoB antisense and MTP inhibitors are approved for homozygous familial hypercholesterolemia.
  • Many HDL-raising drug trials have yielded unpromising results.
  • Enhancing reverse cholesterol transport shows potential as a novel therapeutic strategy.

Conclusions:

  • Novel therapies like PCSK9 antibodies offer significant LDL-C reduction for inadequately controlled hypercholesterolemia.
  • Current HDL-targeting drugs have limited success, suggesting a shift towards targeting reverse cholesterol transport.
  • Future research may focus on modulating reverse cholesterol transport to mitigate cardiovascular risk.